Rebekah Belayneh1, Mitchell S Fourman1, Sumail Bhogal1, Kurt R Weiss2. 1. Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2. Division of Orthopaedic Oncology, Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. weiskr@upmc.edu.
Abstract
PURPOSE OF REVIEW: Osteosarcoma (OSA) is the most common primary tumor of bone, mainly affecting children and adolescents. Here we discuss recent advances in surgical and systemic therapies, and highlight potentially new modalities in preclinical evaluation and prognostication. RECENT FINDINGS: The advent of neoadjuvant and adjuvant chemotherapy has markedly improved the disease-free recurrence and overall survival of OSA. However, treatment efficacy has been stagnant since the 1980s. This plateau has prompted preclinical and clinical research into in precision surgery, inhaled chemotherapy to increase pulmonary drug concentration without systemic side effects, and novel immunomodulators intended to block molecular pathways associated with OSA proliferation and metastasis. With the advent of novel surgical techniques and new forms and vectors for chemotherapy, it is hoped that OSA treatment outcomes will exceed their currently sustained plateau in the near future.
PURPOSE OF REVIEW: Osteosarcoma (OSA) is the most common primary tumor of bone, mainly affecting children and adolescents. Here we discuss recent advances in surgical and systemic therapies, and highlight potentially new modalities in preclinical evaluation and prognostication. RECENT FINDINGS: The advent of neoadjuvant and adjuvant chemotherapy has markedly improved the disease-free recurrence and overall survival of OSA. However, treatment efficacy has been stagnant since the 1980s. This plateau has prompted preclinical and clinical research into in precision surgery, inhaled chemotherapy to increase pulmonary drug concentration without systemic side effects, and novel immunomodulators intended to block molecular pathways associated with OSA proliferation and metastasis. With the advent of novel surgical techniques and new forms and vectors for chemotherapy, it is hoped that OSA treatment outcomes will exceed their currently sustained plateau in the near future.
Authors: Wan Hyeong Cho; Won Seok Song; Dae-Geun Jeon; Chang-Bae Kong; Min Suk Kim; Jun Ah Lee; Ji Young Yoo; Jae Do Kim; Soo-Yong Lee Journal: Ann Surg Oncol Date: 2010-03 Impact factor: 5.344
Authors: Emilios E Pakos; Andreas D Nearchou; Robert J Grimer; Haris D Koumoullis; Adesegun Abudu; Jos A M Bramer; Lee M Jeys; Alessandro Franchi; Guido Scoccianti; Domenico Campanacci; Rodolfo Capanna; Jorge Aparicio; Marie-Dominique Tabone; Gerold Holzer; Fashid Abdolvahab; Philipp Funovics; Martin Dominkus; Inci Ilhan; Su G Berrak; Ana Patino-Garcia; Luis Sierrasesumaga; Mikel San-Julian; Moira Garraus; Antonio Sergio Petrilli; Reynaldo Jesus Garcia Filho; Carla Renata Pacheco Donato Macedo; Maria Teresa de Seixas Alves; Sven Seiwerth; Rajaram Nagarajan; Timothy P Cripe; John P A Ioannidis Journal: Eur J Cancer Date: 2009-04-06 Impact factor: 9.162
Authors: Yangjin Bae; Huan-Chang Zeng; Yi-Ting Chen; Shamika Ketkar; Elda Munivez; Zhiyin Yu; Francis H Gannon; Brendan H Lee Journal: JBMR Plus Date: 2022-04-09